0000000000359856

AUTHOR

Jean-louis Alberini

showing 2 related works from this author

Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers

2015

AbstractFluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) has become a routine imaging modality for many malignancies and its use is currently increasing. In the present review article, we will summarize the evidence for FDG-PET/CT use in digestive cancers (excluding neuroendocrine tumours), and review the existing recommendations. While PET/CT is nowadays considered to be an important tool in the initial workup of oesophageal and anal cancers, new data are emerging regarding its use in assessing therapeutic efficacy, radiotherapy treatment planning, and detection of recurrence in case of isolated tumour marker elevation. Moreover, PET/CT may help …

medicine.medical_specialtyColorectal cancerColonoscopyDigestive System NeoplasmsMultimodal ImagingPatient Care PlanningFluorodeoxyglucose positron emission tomographyFluorodeoxyglucose F18Pancreatic cancerHumansMedicinePositron Emission Tomography-Computed TomographyFluorine-18-fluorodeoxyglucoseHepatologymedicine.diagnostic_testbusiness.industryOesophageal cancerGastroenterologyPancreatic cancerRadiotherapy treatment planningPrognosismedicine.diseaseColorectal cancerFDG-PET/CTAnal canal cancerReview articleNeuroendocrine TumorsPositron-Emission TomographyPractice Guidelines as TopicRadiologyNeoplasm Recurrence LocalRadiopharmaceuticalsTomography X-Ray ComputedbusinessDigestive and Liver Disease
researchProduct

Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies

2016

International audience; Over the past few years, several studies have focused attention on the impact of breast cancer (BC) histological subtype or BC phenotype, as defined by hormone receptors (HR) and HER2 status, on the results of FDG-PET/CT at staging, or during neoadjuvant chemotherapy (NAC). At staging, sclerotic bone metastases from invasive lobular carcinoma (ILC) demonstrated low or no FDG uptake in comparison to metastases from invasive ductal carcinoma (IDC). The CT component of PET/CT imaging should be carefully analyzed in the staging of ILC. In patients with triple negative or HER2-positive tumors, the proportion of extraskeletal metastases is high; this must be taken into acc…

Oncologymedicine.medical_specialtyPathologyStagingPET/CTmedicine.medical_treatmentBiophysicsEstrogen receptorER-positive breast cancerNeoadjuvant chemotherapy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerBreast cancerTriple-negative breast cancerResponse assessmentInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineRadiology Nuclear Medicine and imagingskin and connective tissue diseasesHER2-positive breast cancerTriple-negative breast cancerChemotherapyPET-CTPathological complete responseRadiological and Ultrasound Technologybusiness.industrymedicine.disease18fdg pet ctPrognosis3. Good healthHormone receptor030220 oncology & carcinogenesisInvasive lobular carcinoma(18)FDGbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct